Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HORIZON: ION464 in Multiple System Atrophy
NCT04165486Phase 1Recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jul 2022
- Primary completion
- Sep 2027
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial of ION464 in multiple system atrophy (MSA) (4 arms), sponsored by Ionis Pharmaceuticals. Primary endpoints: Number of Participants with Adverse Events at 36 weeks and Number of Participants with Serious Adverse Events at 36 weeks. Started Jul 2022; status: recruiting.
02
Drugs
ION464
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT04165486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04165486.